國家衛生研究院 NHRI:Item 3990099045/13837
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 908667      線上人數 : 1043
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13837


    題名: Network meta-analysis and trial sequential analysis for atrial fibrillation patients receiving PCI or with ACS
    作者: Yang, SM;Huang, CJ;Chen, CH;Yu, WC;Sung, SH;Guo, CY;Chuang, SY;Cheng, HM;Chiang, CE
    貢獻者: Institute of Population Health Sciences
    摘要: BACKGROUND: In patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI), choosing the most appropriate antithrombotic treatment remains a dilemma. We aimed to compare the relative efficacy and safety outcomes of antithrombotic drugs in patients with AF after undergoing PCI or ACS. METHODS: Randomized controlled trials were systematically searched on PubMed, EMBASE, and the Cochrane Library. Five studies (11,532 patients) were included in the network meta-analysis (NMA). Trial sequential analysis (TSA) was performed to assess the reliability and conclusiveness of the meta-analysis comparing the dual antithrombotic therapy strategies with the triple antithrombotic therapy strategy. RESULTS: Compared with vitamin K antagonist (VKA) + dual antiplatelet therapy (DAPT), novel oral anticoagulant (NOAC) + P2Y12 inhibitor was associated with a significantly better trial-defined primary safety outcome (odds ratio: 0.53; 95% CI: 0.31 - 0.90) and the lowest probability of thrombolysis in myocardial infarction (TIMI) major bleeding and intracranial hemorrhage using the cumulative ranking technique. In patients omitting aspirin, TSA demonstrated conclusive evidence with significant decreases in all safety outcomes and inconclusive evidence with a non-significant increase in in-stent thrombosis (risk ratio: 1.32; TSA-adjusted 95% CI: 0.54 - 3.24) and myocardial infarction (risk ratio: 1.19; TSA-adjusted 95% CI: 0.84 - 1.68). CONCLUSION: In patients with AF receiving PCI or with ACS, NOAC + P2Y12 inhibitor was associated with the lowest bleeding risk but resulted in a statistically non-significant, numerically greater risk for stent thrombosis and myocardial infarction, suggesting that triple antithrombotic therapy (TAT) should still be an option for certain patients at a high risk of stent thrombosis or myocardial infarction.
    日期: 2022-01-01
    關聯: Journal of the Chinese Medical Association. 2022 Jan 1;85(1):59-66.
    Link to: http://dx.doi.org/10.1097/jcma.0000000000000651
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1726-4901&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000838769100009
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85123457260
    顯示於類別:[莊紹源] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB34759208.pdf1830KbAdobe PDF190檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋